Results 111 to 120 of about 337 (145)
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial [PDF]
Lancet, The, 2019 ENLIVEN investigators.[Background] Tenosynovial giant cell tumour (TGCT), a rare, locally aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved systemic therapy.
Sebastian Bauer +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Repurposing of pexidartinib for microglia depletion and renewal
Pharmacology & Therapeutics, 2023Pexidartinib (PLX3397) is a small molecule receptor tyrosine kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) with moderate selectivity over other members of the platelet derived growth factor receptor family. It is approved for treatment of tenosynovial giant cell tumors (TGCT).
Marc-Philipp, Weyer +3 more
openaire +2 more sources
Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review
Anti-Cancer Agents in Medicinal Chemistry, 2021Background: Tenosynovial giant cell tumor refers to a group of rarely occurring tumors that are formed in the joints, which are characterized by pain, swelling, and limitation of movement of the joint. Surgery is the main treatment strategy, but the tumor is likely to recur, especially in pigmented villonodular synovitis, which is the diffuse-type ...
Yunes M.M.A. Alsayadi, Pooja A. Chawla
openaire +2 more sources
Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors
Expert Review of Clinical Pharmacology, 2020Tenosynovial giant cell tumor (TGCT) is a benign mesenchymal tumor arising from the synovium of tendon sheats and joints, driven by colony-stimulating factor 1 (CSF1) over-expression. Standard treatment is surgery, but local recurrences are frequent, especially in diffuse TGCT subtype, rarely cured with surgery.
Giacomo Giulio Baldi +2 more
openaire +2 more sources
Anesthesia & Analgesia
BACKGROUND: Chronic pain is a debilitating medical condition that lacks effective treatments. Increasing evidence suggests that microglia and neuroinflammation underlie pain pathophysiology, which therefore supports a potential strategy for developing pain therapeutics. Here, our study is testing the hypothesis that the promise
Liuyue, Yang +7 more
openaire +2 more sources
BACKGROUND: Chronic pain is a debilitating medical condition that lacks effective treatments. Increasing evidence suggests that microglia and neuroinflammation underlie pain pathophysiology, which therefore supports a potential strategy for developing pain therapeutics. Here, our study is testing the hypothesis that the promise
Liuyue, Yang +7 more
openaire +2 more sources
Sexually dimorphic effects of pexidartinib on nerve injury-induced neuropathic pain in mice
2023Abstract Background It is well-established that spinal microglia and peripheral macrophages play critical roles in the etiology of neuropathic pain; however, growing evidence suggests sex differences in pain hypersensitivity owing to microglia and macrophages.
Fumihiro Saika +6 more
openaire +1 more source
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors.
Oncologist, 2021James H Lewis +2 more
exaly
Role of CSF1R Inhibitor Pexidartinib for the Treatment of Cancer
Russian Journal of Bioorganic Chemistry, 2022openaire +1 more source